Insider & Cluster Buy Highlights – February 14, 2026
📅 Published: February 14, 2026 at 01:35 PM UTC
3 Cluster Buys5 Insider Purchases
On February 14, 2026, this newsletter featured 3 cluster buys and 5 insider purchases detected from SEC Form 4 filings.
📈 Daily Insider & Cluster Buy Highlights – February 14, 2026
Here are some of the most interesting insider and cluster buying signals from the last 7 days.
⚠️ For information purposes only.
This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 About Fair Value:
The Fair Value shown for each company is calculated using a Levered Discounted Cash Flow (DCF) model. This method estimates the intrinsic value of a stock by projecting future cash flows and discounting them back to present value, accounting for the company's debt structure. A positive percentage difference indicates the stock may be undervalued relative to this model, while a negative percentage suggests it may be overvalued. Fair value calculations are estimates and should be considered alongside other factors.
🔥 Notable Cluster Buys (≥ $500,000)
Zenas BioPharma, Inc.View ChartFinancials
Ticker: ZBIO
$26.40
Current Price
52W: Low: $6.11 | High: $44.60
$7.56
Fair Value
Participants: 2 insiders
Total Shares: 45,845
Total Value: $1,084,408
Timeframe: 2 days
Date Range: Feb 11, 2026 to Feb 13, 2026
👥 Participant Details:
Lu Hongbo
Director
Date: Feb 11, 2026
25,985 shares
$584,662
@ $22.50/share
P&L: +17.3% (+$101,341)
Allen Patricia L
Director
Date: Feb 12, 2026
5,000 shares
$132,500
@ $26.50/share
P&L: -0.4% ($500)
Allen Patricia L
Director
Date: Feb 12, 2026
5,000 shares
$118,850
@ $23.77/share
P&L: +11.1% (+$13,150)
Allen Patricia L
Director
Date: Feb 12, 2026
5,700 shares
$138,738
@ $24.34/share
P&L: +8.5% (+$11,742)
Allen Patricia L
Director
Date: Feb 13, 2026
4,160 shares
$109,658
@ $26.36/share
P&L: +0.2% (+$166)
📈 Average P&L: +7.3% (+25,180)
Current Price: $26.40
📊 Valuation & Analyst Info:
Fair Value: $7.56 (71.4% overvalued vs current price)
Analyst Rating: C+
Avg Price Target: $33.50 (+26.9% vs current)
📰 Recent News (Last 7 Days):
PRNewsWire • Feb 12, 2026
NEW YORK, Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised to c...
GlobeNewsWire • Feb 09, 2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) -
📊 Recent Earnings: Feb 11, 2026
C.H. Robinson Worldwide, Inc.View ChartFinancials
Ticker: CHRW
$176.01
Current Price
52W: Low: $84.68 | High: $203.34
$56.58
Fair Value
Participants: 4 insiders
Total Shares: 3,042
Total Value: $501,637
Timeframe: 0 days
Date Range: Feb 12, 2026 to Feb 12, 2026
👥 Participant Details:
Lee Damon J.
Officer
Date: Feb 12, 2026
620 shares
$100,764
@ $162.52/share
P&L: +8.3% (+$8,362)
Bozeman David P
Director
Date: Feb 12, 2026
1,223 shares
$199,771
@ $163.34/share
P&L: +7.8% (+$15,489)
Castagnetto Michael D.
Officer
Date: Feb 12, 2026
594 shares
$100,000
@ $168.24/share
P&L: +4.6% (+$4,618)
RAJAN ARUN
Officer
Date: Feb 12, 2026
605 shares
$101,102
@ $167.11/share
P&L: +5.3% (+$5,384)
📈 Average P&L: +6.5% (+8,464)
Current Price: $176.01
📊 Valuation & Analyst Info:
Fair Value: $56.58 (67.9% overvalued vs current price)
Analyst Rating: B
Avg Price Target: $184.52 (+4.8% vs current)
📰 Recent News (Last 7 Days):
GuruFocus • Feb 13, 2026
Guru Stock PicksRobert Bruce has made the following transactions:Reduce in NEE by 1.49%Ray Dalio has made the following transactions:Reduce in CNX by 13.43%Sold
Zacks Investment Research • Feb 13, 2026
Investors looking for stocks in the Transportation - Services sector might want to consider either Kuehne & Nagel International Ag (KHNGY) or C.H. Robinson Worldwide (CHRW).
Fool - Investing News • Feb 13, 2026
ANET pops as results impress, trucking stocks hit by AI disruption, and more
Fool - Investing News • Feb 12, 2026
On Feb. 12, 2026, a fresh wave of AI launches rattled Wall Street as investors questioned how much automation could disrupt real estate, logistics, and other industries.
Market Watch • Feb 12, 2026
Shares of C.H. Robinson Worldwide on Thursday headed for their steepest drop ever, as investors seemed to focus their fears about AI disruption onto the transportation and logistics company.
Zacks Investment Research • Feb 11, 2026
PH, GS, GE, CHRW and CRS are five old-economy stocks that posted strong quarterly earnings, signaling potential upside in 2026.
Defense World • Feb 11, 2026
Envestnet Asset Management Inc. cut its stake in C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) by 7.6% in the third quarter, according to the company in its most recent filing with the Securities and E...
Defense World • Feb 10, 2026
Oppenheimer Asset Management Inc. reduced its holdings in shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) by 31.8% in the third quarter, according to the company in its most recent 13F filing w...
Defense World • Feb 10, 2026
C.H. Robinson Worldwide (NASDAQ: CHRW - Get Free Report) and Callan JMB (NASDAQ: CJMB - Get Free Report) are both transportation companies, but which is the better stock? We will compare the two compa...
Defense World • Feb 09, 2026
ProShare Advisors LLC decreased its position in shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) by 7.5% in the third quarter, according to the company in its most recent Form 13F filing with th...
Defense World • Feb 09, 2026
BI Asset Management Fondsmaeglerselskab A S grew its holdings in C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) by 91.8% during the third quarter, according to its most recent disclosure with the Securi...
QuidelOrtho CorporationView ChartFinancials
Ticker: QDEL
$23.58
Current Price
52W: Low: $19.50 | High: $42.50
$88.78
Fair Value
Participants: 3 insiders
Total Shares: 23,910
Total Value: $567,989
Timeframe: 0 days
Date Range: Feb 13, 2026 to Feb 13, 2026
👥 Participant Details:
Blaser Brian J.
Officer
Date: Feb 13, 2026
10,540 shares
$248,661
@ $23.59/share
P&L: -0.1% ($128)
Strobeck Matthew
Director
Date: Feb 13, 2026
10,000 shares
$239,586
@ $23.96/share
P&L: -1.6% ($3,786)
Busky Joseph M.
Officer
Date: Feb 13, 2026
3,370 shares
$79,742
@ $23.66/share
P&L: -0.3% ($277)
📉 Average P&L: -0.7% (-1,397)
Current Price: $23.58
📊 Valuation & Analyst Info:
Fair Value: $88.78 (276.5% undervalued vs current price)
Analyst Rating: C+
Avg Price Target: $32.50 (+37.8% vs current)
📰 Recent News (Last 7 Days):
Defense World • Feb 13, 2026
QuidelOrtho (NASDAQ: QDEL - Get Free Report) and Oramed Pharmaceuticals (NASDAQ: ORMP - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two...
Zacks Investment Research • Feb 12, 2026
QDEL beats Q4 estimates as Labs and global growth lift sales, but shrinking margins and respiratory weakness weigh on profits.
Seeking Alpha • Feb 11, 2026
QuidelOrtho Corporation (QDEL) Q4 2025 Earnings Call Transcript
Zacks Investment Research • Feb 11, 2026
QuidelOrtho (QDEL) came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.
PRNewsWire • Feb 11, 2026
― Delivered 6% Labs and 9% TRIAGE™ growth, as reported, and 240 bps of adjusted EBITDA margin expansion in FY25 ― ― Continued growth and margin expansion expected in FY26; free cash flow expected to i...
📊 Recent Earnings: Feb 11, 2026
EPS: $0.46 (est: $0.43)
Revenue: $723,600,000M (est: $712,454,830M)
💼 Notable Individual Insider Buys (≥ $100,000)
$69.70
Current Price
$384.63
Fair Value
Transaction Date: Feb 12, 2026
Shares: 17,599
Purchase Price: $71.88
Purchase Value: $1,265,030
📉
P&L: 3.0% ($38,380 loss)
📊 Valuation & Analyst Info:
Fair Value: $384.63 (451.8% undervalued vs current price)
Analyst Rating: B-
Avg Price Target: $72.31 (+3.7% vs current)
📰 Recent News (Last 7 Days):
Defense World • Feb 14, 2026
Atria Investments Inc lowered its position in W.R. Berkley Corporation (NYSE: WRB) by 10.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commissio...
Business Wire • Feb 13, 2026
GREENWICH, Conn.--(BUSINESS WIRE)--W. R. Berkley Corporation (NYSE: WRB) announced today that its Board of Directors has declared a regular quarterly cash dividend on its common stock of 9 cents per s...
Zacks Investment Research • Feb 13, 2026
Investors looking for stocks in the Insurance - Property and Casualty sector might want to consider either Tokio Marine Holdings Inc. (TKOMY) or W.R. Berkley (WRB).
Seeking Alpha • Feb 11, 2026
W. R. Berkley Corporation (WRB) Presents at Bank of America Financial Services Conference 2026 Transcript
Seeking Alpha • Feb 10, 2026
W. R. Berkley Corporation (WRB) Presents at UBS Financial Services Conference 2026 Transcript
GuruFocus • Feb 09, 2026
Jefferies Group (Trades, Portfolio)'s Strategic Moves in Q4 2025: A Detailed Analysis Jefferies Group (Trades, Portfolio) recently submitted its 13F filing for
24/7 Wall Street • Feb 09, 2026
Insider buying can signal confidence when executives and major shareholders put their own money on the line.
Defense World • Feb 09, 2026
First American Financial (NYSE: FAF - Get Free Report) and W.R. Berkley (NYSE: WRB - Get Free Report) are both finance companies, but which is the superior business? We will compare the two companies ...
$69.70
Current Price
$384.63
Fair Value
Transaction Date: Feb 13, 2026
Shares: 15,406
Purchase Price: $69.73
Purchase Value: $1,074,336
📉
P&L: 0.1% ($538 loss)
📊 Valuation & Analyst Info:
Fair Value: $384.63 (451.8% undervalued vs current price)
Analyst Rating: B-
Avg Price Target: $72.31 (+3.7% vs current)
📰 Recent News (Last 7 Days):
Defense World • Feb 14, 2026
Atria Investments Inc lowered its position in W.R. Berkley Corporation (NYSE: WRB) by 10.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commissio...
Business Wire • Feb 13, 2026
GREENWICH, Conn.--(BUSINESS WIRE)--W. R. Berkley Corporation (NYSE: WRB) announced today that its Board of Directors has declared a regular quarterly cash dividend on its common stock of 9 cents per s...
Zacks Investment Research • Feb 13, 2026
Investors looking for stocks in the Insurance - Property and Casualty sector might want to consider either Tokio Marine Holdings Inc. (TKOMY) or W.R. Berkley (WRB).
Seeking Alpha • Feb 11, 2026
W. R. Berkley Corporation (WRB) Presents at Bank of America Financial Services Conference 2026 Transcript
Seeking Alpha • Feb 10, 2026
W. R. Berkley Corporation (WRB) Presents at UBS Financial Services Conference 2026 Transcript
GuruFocus • Feb 09, 2026
Jefferies Group (Trades, Portfolio)'s Strategic Moves in Q4 2025: A Detailed Analysis Jefferies Group (Trades, Portfolio) recently submitted its 13F filing for
24/7 Wall Street • Feb 09, 2026
Insider buying can signal confidence when executives and major shareholders put their own money on the line.
Defense World • Feb 09, 2026
First American Financial (NYSE: FAF - Get Free Report) and W.R. Berkley (NYSE: WRB - Get Free Report) are both finance companies, but which is the superior business? We will compare the two companies ...
$8.21
Current Price
Transaction Date: Nov 18, 2025
Shares: 64,750
Purchase Price: $7.67
Purchase Value: $496,632
📈
P&L: 7.0% ($34,965 gain)
📊 Valuation & Analyst Info:
Analyst Rating: C
Avg Price Target: $12.00 (+46.2% vs current)
📰 Recent News (Last 7 Days):
Benzinga • Feb 10, 2026
Personalis (PSNL) stock up in premarket on Medicare coverage for its NeXT Personal test for lung cancer surveillance.
Business Wire • Feb 10, 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular res...
📅 Upcoming Earnings: Feb 26, 2026
EPS Estimate: $-0.31
$69.70
Current Price
$384.63
Fair Value
Transaction Date: Feb 13, 2026
Shares: 4,314
Purchase Price: $70.30
Purchase Value: $303,264
📉
P&L: 0.9% ($2,578 loss)
📊 Valuation & Analyst Info:
Fair Value: $384.63 (451.8% undervalued vs current price)
Analyst Rating: B-
Avg Price Target: $72.31 (+3.7% vs current)
📰 Recent News (Last 7 Days):
Defense World • Feb 14, 2026
Atria Investments Inc lowered its position in W.R. Berkley Corporation (NYSE: WRB) by 10.2% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commissio...
Business Wire • Feb 13, 2026
GREENWICH, Conn.--(BUSINESS WIRE)--W. R. Berkley Corporation (NYSE: WRB) announced today that its Board of Directors has declared a regular quarterly cash dividend on its common stock of 9 cents per s...
Zacks Investment Research • Feb 13, 2026
Investors looking for stocks in the Insurance - Property and Casualty sector might want to consider either Tokio Marine Holdings Inc. (TKOMY) or W.R. Berkley (WRB).
Seeking Alpha • Feb 11, 2026
W. R. Berkley Corporation (WRB) Presents at Bank of America Financial Services Conference 2026 Transcript
Seeking Alpha • Feb 10, 2026
W. R. Berkley Corporation (WRB) Presents at UBS Financial Services Conference 2026 Transcript
GuruFocus • Feb 09, 2026
Jefferies Group (Trades, Portfolio)'s Strategic Moves in Q4 2025: A Detailed Analysis Jefferies Group (Trades, Portfolio) recently submitted its 13F filing for
24/7 Wall Street • Feb 09, 2026
Insider buying can signal confidence when executives and major shareholders put their own money on the line.
Defense World • Feb 09, 2026
First American Financial (NYSE: FAF - Get Free Report) and W.R. Berkley (NYSE: WRB - Get Free Report) are both finance companies, but which is the superior business? We will compare the two companies ...
$8.21
Current Price
Transaction Date: Dec 22, 2025
Shares: 28,000
Purchase Price: $8.93
Purchase Value: $250,040
📉
P&L: 8.1% ($20,160 loss)
📊 Valuation & Analyst Info:
Analyst Rating: C
Avg Price Target: $12.00 (+46.2% vs current)
📰 Recent News (Last 7 Days):
Benzinga • Feb 10, 2026
Personalis (PSNL) stock up in premarket on Medicare coverage for its NeXT Personal test for lung cancer surveillance.
Business Wire • Feb 10, 2026
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced Medicare coverage for the company's NeXT Personal molecular res...
📅 Upcoming Earnings: Feb 26, 2026
EPS Estimate: $-0.31
This newsletter is generated automatically. Please verify all information independently before making investment decisions.
Want to receive these newsletters in your inbox? Sign up here